EUVIMEDEUVIMED entdecken
Open Access

Development of phenothiazine-based inhibitors towards drug-resistant glioblastoma

Gaurav Rai, Deepika Khasa, Sivapriya Kirubakaran iD

RSC Medicinal Chemistry · 2026

DOI: 10.1039/d6md00465b ↗

Kurz gefasst

Fachartikel in der Zeitschrift RSC Medicinal Chemistry, 2026. Verfasst von Gaurav Rai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Indian Institute of Technology Gandhinagar Palaj Campus, Palaj Gandhinagar-382055 Gujarat India priyak@iitgn.ac.in. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministry of Education, India.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A phenothiazine-based TTK inhibitor, G17b, overcomes temozolomide resistance in glioblastoma by triggering ROS-driven apoptosis, offering a CNS-penetrant starting point for future drug optimization.

Autor:innen und Institutionen

  • Department of Chemistry, Indian Institute of Technology Gandhinagar Palaj Campus, Palaj Gandhinagar-382055 Gujarat India priyak@iitgn.ac.in.

ORCID-Profile: Sivapriya Kirubakaran

Förderung

  • Ministry of Education, India

Zitieren

APA

Rai, G., Khasa, D., & Kirubakaran, S. (2026). Development of phenothiazine-based inhibitors towards drug-resistant glioblastoma. RSC Medicinal Chemistry. https://doi.org/10.1039/d6md00465b

Vancouver

Rai G, Khasa D, Kirubakaran S. Development of phenothiazine-based inhibitors towards drug-resistant glioblastoma. RSC Medicinal Chemistry. 2026. doi:10.1039/d6md00465b

BibTeX
@article{Rai2026,
  author = {Rai, Gaurav and Khasa, Deepika and Kirubakaran, Sivapriya},
  title = {Development of phenothiazine-based inhibitors towards drug-resistant glioblastoma},
  journal = {RSC Medicinal Chemistry},
  year = {2026},
  doi = {10.1039/d6md00465b}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche